Medical Director, Hematology/Oncology — Lead Modesto Cancer Program

AOIA; Modesto (CA); On-site; USD 540,000 - 660,000; Full time

Benefits offered by this job

401(k) contribution

Shareholder track

CME allowance

Health, dental, vision, life

Malpractice tail

Profit sharing

Relocation assistance

Job summary

Gould Medical Group in Modesto, CA is seeking a BE/BC Hematology/Oncology Medical Director to lead a new, unified oncology program as Sutter Health builds the cancer center. This role combines clinical leadership with program development and cross-department collaboration across GMG’s oncology services.

The position includes a 0.75 FTE clinical Hematology/Oncology and 0.25 FTE Medical Director, with base salary starting at $600,000 and RVU-based compensation in years two and beyond.

Qualifications

• MD or DO, board-certified in Medical Oncology (Hematology/Oncology background also considered).
• Established regional or national reputation as a clinical and program leader in oncology.

Responsibilities

• Lead the oncology service line across GMG and partner with Sutter Health leadership.
• Recruit top talent to close gaps (e.g., gynecologic oncology).
• Establish and chair a multidisciplinary tumor board covering multiple oncologic specialties.
• Drive program quality and accreditation strategies for a comprehensive community cancer program.
• Represent GMG's oncology program to referring physicians, hospital leadership, and the community.

Skills

Leadership

Recruitment

Communication

Education

MD/DO

Tools

Epic EHR

Job description

Gould Medical Group in Modesto, CA is seeking a BE/BC Hematology/Oncology Medical Director to lead a new, unified oncology program as Sutter Health builds the cancer center. This role combines clinical leadership with program development and cross-department collaboration across GMG’s oncology services.

The position includes a 0.75 FTE clinical Hematology/Oncology and 0.25 FTE Medical Director, with base salary starting at $600,000 and RVU-based compensation in years two and beyond.